Pictet Asset Management
YMAB

Pictet Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Pictet Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-441,934
Closed -$1.96M – 2059
2025
Q1 		$1.96M Sell
441,934
-314,363
-42% -$1.83M ﹤0.01% 890
2024
Q4 		$5.92M Buy
756,297
+68,317
+10% +$832K 0.01% 782
2024
Q3 		$9.05M Buy
687,980
+28,308
+4% +$359K 0.01% 679
2024
Q2 		$7.97M Sell
659,672
-86,429
-12% -$1.17M 0.01% 680
2024
Q1 		$12.1M Buy
+746,101
New +$10.1M 0.01% 609

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Pictet Asset Management's YMAB Position: Q2 2025 in Review

Pictet Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 441,934 shares — an estimated $1.96M sold.

Pictet Asset Management first reported a position in YMAB in Q1 2024 and held it in 5 quarters. The position peaked at $12.1M in Q1 2024. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • Pictet Asset Management reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Pictet Asset Management sold 441,934 Y-mAbs Therapeutics shares in Q2 2025, an estimated $1.96M.
  • Pictet Asset Management first reported a position in Y-mAbs Therapeutics in Q1 2024 and held it in 5 quarters.
  • Pictet Asset Management's Y-mAbs Therapeutics position peaked at $12.1M in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on Pictet Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.